Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.659
-0.018 (-2.67%)
Mar 12, 2025, 4:00 PM EST - Market closed
Rallybio Employees
Rallybio had 43 employees as of December 31, 2023. The number of employees increased by 2 or 4.88% compared to the previous year.
Employees
43
Change (1Y)
2
Growth (1Y)
4.88%
Revenue / Employee
$13,907
Profits / Employee
-$1,557,512
Market Cap
27.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
RLYB News
- 15 days ago - Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 4 weeks ago - Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire
- 2 months ago - Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - Business Wire
- 3 months ago - Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting - Business Wire
- 3 months ago - Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
- 3 months ago - Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
- 3 months ago - Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Business Wire
- 3 months ago - Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire